Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 381

1.

Opioids: The Painful Public Health Reality.

Tyndale RF, Sellers EM.

Clin Pharmacol Ther. 2018 Jun;103(6):924-935. doi: 10.1002/cpt.1074.

PMID:
29878319
2.

Improving the Clinical Pharmacologic Assessment of Abuse Potential: Part 2: Optimizing the Design of Human Abuse Potential Studies.

Sellers EM.

J Clin Psychopharmacol. 2018 Apr;38(2):113-118. doi: 10.1097/JCP.0000000000000838. Review.

PMID:
29360651
3.

Improving the Clinical Pharmacologic Assessment of Abuse Potential: Part 1: Regulatory Context and Risk Management.

Sellers EM.

J Clin Psychopharmacol. 2018 Feb;38(1):11-18. doi: 10.1097/JCP.0000000000000835.

PMID:
29215386
4.

Studies with psychedelic drugs in human volunteers.

Sellers EM, Romach MK, Leiderman DB.

Neuropharmacology. 2017 Nov 21. pii: S0028-3908(17)30546-4. doi: 10.1016/j.neuropharm.2017.11.029. [Epub ahead of print] Review.

PMID:
29162429
5.

Human abuse potential of brivaracetam in healthy recreational central nervous system depressant users.

Schoedel KA, Stockis A, Sellers EM.

Epilepsy Behav. 2018 Jan;78:194-201. doi: 10.1016/j.yebeh.2017.09.008. Epub 2017 Nov 15.

PMID:
29153631
6.

Categorization of Abuse Potential-Related Adverse Events.

Sellers EM, Romach MK.

Clin Pharmacol Drug Dev. 2017 Oct 11. doi: 10.1002/cpdd.394. [Epub ahead of print]

PMID:
29024490
7.

Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Crossover Study Evaluating the Abuse Potential of the Antiepileptic Drug Lacosamide in Healthy Recreational Drug Users.

Schoedel KA, Andreas JO, Doty P, Eckhardt K, Sellers EM.

J Clin Psychopharmacol. 2017 Dec;37(6):675-683. doi: 10.1097/JCP.0000000000000780.

PMID:
28926353
8.

Psychedelic Drugs as Therapeutics: No Illusions About the Challenges.

Sellers EM, Leiderman DB.

Clin Pharmacol Ther. 2018 Apr;103(4):561-564. doi: 10.1002/cpt.776. Epub 2017 Aug 24.

PMID:
28836272
9.

Psilocybin: Good Trip or Bad Trip.

Sellers EM.

Clin Pharmacol Ther. 2017 Oct;102(4):580-584. doi: 10.1002/cpt.697. Epub 2017 May 26.

PMID:
28548221
10.

Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist.

Levy-Cooperman N, McIntyre G, Bonifacio L, McDonnell M, Davenport JM, Covington PS, Dove LS, Sellers EM.

J Pharmacol Exp Ther. 2016 Dec;359(3):471-481. Epub 2016 Sep 19.

11.

Deconstructing Designer Drugs.

Sellers EM.

Clin Pharmacol Ther. 2017 Feb;101(2):167-169. doi: 10.1002/cpt.462. Epub 2016 Nov 16.

PMID:
27564430
12.

Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.

Schoedel KA, Sun H, Sellers EM, Faulknor J, Levy-Cooperman N, Li X, Kennedy WP, Cha JH, Lewis NM, Liu W, Bondiskey P, McCrea JB, Panebianco DL, Troyer MD, Wagner JA.

J Clin Psychopharmacol. 2016 Aug;36(4):314-23. doi: 10.1097/JCP.0000000000000516.

PMID:
27253658
13.

The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.

Coplan PM, Chilcoat HD, Butler SF, Sellers EM, Kadakia A, Harikrishnan V, Haddox JD, Dart RC.

Clin Pharmacol Ther. 2016 Sep;100(3):275-86. doi: 10.1002/cpt.390. Epub 2016 Jun 22. Erratum in: Clin Pharmacol Ther. 2017 Apr;101(4):541.

14.

Assessment of Pharmacokinetic and Pharmacodynamic Interactions Between Albumin-Fused Mutated Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine Users.

Shram MJ, Cohen-Barak O, Chakraborty B, Bassan M, Schoedel KA, Hallak H, Eyal E, Weiss S, Gilgun-Serki Y, Sellers EM, Faulknor J, Spiegelstein O.

J Clin Psychopharmacol. 2015 Aug;35(4):396-405. doi: 10.1097/JCP.0000000000000347. Erratum in: J Clin Psychopharmacol. 2016 Oct;36(5):537. Gilgun, Yossi [corrected to Gilgun-Serki, Yossi].

PMID:
26082975
15.

Use of Remifentanil in a Novel Clinical Paradigm to Characterize Onset and Duration of Opioid Blockade by Samidorphan, a Potent μ-Receptor Antagonist.

Shram MJ, Silverman B, Ehrich E, Sellers EM, Turncliff R.

J Clin Psychopharmacol. 2015 Jun;35(3):242-9. doi: 10.1097/JCP.0000000000000320.

16.

Claudio A. Naranjo, MD (1945-2014).

Sellers EM.

Clin Pharmacol Ther. 2015 Jan;97(1):14-5. doi: 10.1002/cpt.12. Epub 2014 Nov 25. No abstract available.

PMID:
25670377
17.

Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect.

Schoedel KA, Morrow SA, Sellers EM.

Neuropsychiatr Dis Treat. 2014 Jun 26;10:1161-74. doi: 10.2147/NDT.S30713. eCollection 2014. Review.

18.

Human abuse liability evaluation of CNS stimulant drugs.

Romach MK, Schoedel KA, Sellers EM.

Neuropharmacology. 2014 Dec;87:81-90. doi: 10.1016/j.neuropharm.2014.04.014. Epub 2014 Apr 30. Review.

PMID:
24793872
19.

Preventing and managing aberrant drug-related behavior in primary care: systematic review of outcomes evidence.

Argoff CE, Kahan M, Sellers EM.

J Opioid Manag. 2014 Mar-Apr;10(2):119-34. doi: 10.5055/jom.2014.0201. Review.

PMID:
24715667
20.

Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users.

Cruz HG, Hoever P, Chakraborty B, Schoedel K, Sellers EM, Dingemanse J.

CNS Drugs. 2014 Apr;28(4):361-72. doi: 10.1007/s40263-014-0150-x.

PMID:
24627301
21.

Brain Network Activation (BNA) reveals scopolamine-induced impairment of visual working memory.

Reches A, Levy-Cooperman N, Laufer I, Shani-Hershkovitch R, Ziv K, Kerem D, Gal N, Stern Y, Cukierman G, Romach MK, Sellers EM, Geva AB.

J Mol Neurosci. 2014 Sep;54(1):59-70. doi: 10.1007/s12031-014-0250-6. Epub 2014 Feb 18.

PMID:
24535560
22.

Mitigating the risk of opioid abuse through a balanced undergraduate pain medicine curriculum.

Morley-Forster PK, Pergolizzi JV, Taylor R Jr, Axford-Gatley RA, Sellers EM.

J Pain Res. 2013 Dec 4;6:791-801. doi: 10.2147/JPR.S47192. Review.

23.

Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users.

Harris SC, Perrino PJ, Smith I, Shram MJ, Colucci SV, Bartlett C, Sellers EM.

J Clin Pharmacol. 2014 Apr;54(4):468-77. doi: 10.1002/jcph.235. Epub 2013 Dec 11.

24.

From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists.

Higgins GA, Sellers EM, Fletcher PJ.

Trends Pharmacol Sci. 2013 Oct;34(10):560-70. doi: 10.1016/j.tips.2013.08.001. Epub 2013 Sep 13. Review.

PMID:
24041919
25.

A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray.

Sellers EM, Schoedel K, Bartlett C, Romach M, Russo EB, Stott CG, Wright S, White L, Duncombe P, Chen CF.

Clin Pharmacol Drug Dev. 2013 Jul;2(3):285-94. doi: 10.1002/cpdd.36. Epub 2013 May 14.

PMID:
27121791
26.

Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.

Sellers EM, Perrino PJ, Colucci SV, Harris SC.

J Psychopharmacol. 2013 Sep;27(9):808-16. doi: 10.1177/0269881113493364. Epub 2013 Jun 19.

PMID:
23784739
27.

Update on tamper-resistant drug formulations.

Romach MK, Schoedel KA, Sellers EM.

Drug Alcohol Depend. 2013 Jun 1;130(1-3):13-23. doi: 10.1016/j.drugalcdep.2012.12.028. Epub 2013 Feb 13. Review.

PMID:
23415386
28.

Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations.

Comer SD, Zacny JP, Dworkin RH, Turk DC, Bigelow GE, Foltin RW, Jasinski DR, Sellers EM, Adams EH, Balster R, Burke LB, Cerny I, Colucci RD, Cone E, Cowan P, Farrar JT, Haddox JD, Haythornthwaite JA, Hertz S, Jay GW, Johanson CE, Junor R, Katz NP, Klein M, Kopecky EA, Leiderman DB, McDermott MP, O'Brien C, O'Connor AB, Palmer PP, Raja SN, Rappaport BA, Rauschkolb C, Rowbotham MC, Sampaio C, Setnik B, Sokolowska M, Stauffer JW, Walsh SL.

Pain. 2012 Dec;153(12):2315-24. doi: 10.1016/j.pain.2012.07.035. Epub 2012 Sep 19.

29.

Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users.

Schoedel KA, Addy C, Chakraborty B, Rosko K, Dunbar S, Maes A, Chen N, Stoch SA, Wagner J, Chodakewitz J, Sellers EM.

J Clin Psychopharmacol. 2012 Aug;32(4):492-502. doi: 10.1097/JCP.0b013e31825d380d.

PMID:
22722508
30.

A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers.

Pope LE, Schoedel KA, Bartlett C, Sellers EM.

Clin Drug Investig. 2012 Aug 1;32(8):e1-15. doi: 10.2165/11633850-000000000-00000.

31.

Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria.

Shram MJ, Quinn AM, Chen N, Faulknor J, Luong D, Sellers EM, Endrenyi L.

Clin Ther. 2012 May;34(5):1170-81. doi: 10.1016/j.clinthera.2012.02.010. Epub 2012 Apr 17.

PMID:
22512898
32.

Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers.

Schoedel KA, Pope LE, Sellers EM.

Clin Drug Investig. 2012 Mar 1;32(3):157-69. doi: 10.2165/11599870-000000000-00000.

PMID:
22283559
33.

Effects of low-dose opioids on cognitive dysfunction.

McMorn S, Schoedel KA, Sellers EM.

J Clin Oncol. 2011 Nov 10;29(32):4342-3; author reply 4343-4. doi: 10.1200/JCO.2011.38.2309. Epub 2011 Oct 3. No abstract available.

PMID:
21969492
34.

Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users.

Schoedel KA, McMorn S, Chakraborty B, Potts SL, Zerbe K, Sellers EM.

J Opioid Manag. 2011 May-Jun;7(3):179-92.

PMID:
21823549
35.

A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use.

Schoedel KA, Chen N, Hilliard A, White L, Stott C, Russo E, Wright S, Guy G, Romach MK, Sellers EM.

Hum Psychopharmacol. 2011 Apr;26(3):224-36. doi: 10.1002/hup.1196.

PMID:
21671456
36.

Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users.

Shram MJ, Schoedel KA, Bartlett C, Shazer RL, Anderson CM, Sellers EM.

Clin Pharmacol Ther. 2011 May;89(5):683-92. doi: 10.1038/clpt.2011.20. Epub 2011 Mar 16.

PMID:
21412231
37.

Oral ketamine as a positive control in human abuse potential studies.

Shram MJ, Sellers EM, Romach MK.

Drug Alcohol Depend. 2011 Apr 1;114(2-3):185-93. doi: 10.1016/j.drugalcdep.2010.10.002. Epub 2010 Nov 24.

PMID:
21109365
38.

Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone.

Schoedel KA, McMorn S, Chakraborty B, Zerbe K, Sellers EM.

Pain Physician. 2010 Nov-Dec;13(6):561-73.

39.

The role of adverse events and related safety data in the pre-market evaluation of drug abuse potential.

Mansbach RS, Schoedel KA, Kittrelle JP, Sellers EM.

Drug Alcohol Depend. 2010 Dec 1;112(3):173-7. doi: 10.1016/j.drugalcdep.2010.07.001.

PMID:
20817417
40.

Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers.

Milovan D, Almeida L, Romach MK, Nunes T, Rocha JF, Sokowloska M, Sellers EM, Soares-da-Silva P.

Epilepsy Behav. 2010 Aug;18(4):366-73. doi: 10.1016/j.yebeh.2010.04.022. Epub 2010 Jun 18.

PMID:
20708576
41.

Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users.

Schoedel KA, Meier D, Chakraborty B, Manniche PM, Sellers EM.

Clin Pharmacol Ther. 2010 Jul;88(1):69-78. doi: 10.1038/clpt.2010.67. Epub 2010 Jun 2.

PMID:
20520602
42.

New CYP2A6 gene deletion and conversion variants in a population of Black African descent.

Mwenifumbo JC, Zhou Q, Benowitz NL, Sellers EM, Tyndale RF.

Pharmacogenomics. 2010 Feb;11(2):189-98. doi: 10.2217/pgs.09.144.

43.

Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone.

Shram MJ, Sathyan G, Khanna S, Tudor IC, Nath R, Thipphawong J, Sellers EM.

J Clin Psychopharmacol. 2010 Feb;30(1):25-33. doi: 10.1097/JCP.0b013e3181c8f088.

PMID:
20075644
44.

Effect of metabolic blockade on the psychoactive effects of dextromethorphan.

Zawertailo LA, Tyndale RF, Busto U, Sellers EM.

Hum Psychopharmacol. 2010 Jan;25(1):71-9. doi: 10.1002/hup.1086.

PMID:
20041473
45.

Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: expert panel report.

Johanson CE, Balster RL, Henningfield JE, Schuster CR, Anthony JC, Barthwell AG, Coleman JJ, Dart RC, Gorodetzky CW, O'Keeffe C, Sellers EM, Vocci F, Walsh SL.

Drug Alcohol Depend. 2009 Dec 1;105 Suppl 1:S65-71. doi: 10.1016/j.drugalcdep.2009.08.006. Epub 2009 Sep 23.

46.

A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo.

Al Koudsi N, Ahluwalia JS, Lin SK, Sellers EM, Tyndale RF.

Pharmacogenomics J. 2009 Aug;9(4):274-82. doi: 10.1038/tpj.2009.11. Epub 2009 Apr 14.

47.

Socioeconomic and drug use determinants of smoking status in an urban adult population of Black African descent.

Mwenifumbo JC, Sellers EM, Tyndale RF.

Nicotine Tob Res. 2008 Aug;10(8):1319-25. doi: 10.1080/14622200802238894.

48.

Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent.

Mwenifumbo JC, Al Koudsi N, Ho MK, Zhou Q, Hoffmann EB, Sellers EM, Tyndale RF.

Hum Mutat. 2008 May;29(5):679-88. doi: 10.1002/humu.20698.

PMID:
18360915
49.

Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers.

McColl SL, Burstein AH, Reeves KR, Billing CB Jr, Stolar M, Sellers EM.

Clin Pharmacol Ther. 2008 Apr;83(4):607-14. doi: 10.1038/sj.clpt.6100510. Epub 2008 Feb 20.

PMID:
18288085
50.

Assessing abuse liability during drug development: changing standards and expectations.

Schoedel KA, Sellers EM.

Clin Pharmacol Ther. 2008 Apr;83(4):622-6. doi: 10.1038/sj.clpt.6100492. Epub 2008 Jan 23. Review.

PMID:
18212799

Supplemental Content

Loading ...
Support Center